Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 501–600 of 684
Zhang, S., Wang, Y., Liu, W., Xie, Y., Liu, Y., Xu, W., Tang, L., Wang, J., & Zhao, G. (2014) · Chemical Research in Chinese Universities · doi:10.1007/s40242-014-4043-9 · Cited by 3
DIABETES MELLITUS: A REVIEW WITH EDGE OF SGLT2 INHIBITORS
Singh, R. J., Gupta, A., & Kohli, K. (2018) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2018v10i5.29693 · Cited by 3
“It inhibits the renal glucose reabsorption by estimated 40– 50%, with the maximum amount of excreted glucose of 80–85 g/day [10, 12].”
BackgroundPeng, P., Zhao, C., Yang, J.-T., Liu, X., Yu, J., & Zhang, F. (2022) · Organic Preparations and Procedures International · doi:10.1080/00304948.2021.2022922 · Cited by 3
Diabetes and Antidiabetic Drugs
Khan, M. O. F. (2024) · Medicinal chemistry for pharmacy students · doi:10.2174/9789815179729124030009 · Cited by 12
Zargar, I. A., Rasool, B., Bappa, S. K., & Mukherjee, D. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob01172d · Cited by 3
Facile synthesis of enantiomerically pure 1-(5-bromo-2-chlorophenyl)-1-(4-ethoxyphenyl)ethane
Zhang, S., Wang, W., Li, C., Liu, P., Xu, W., Tang, L., Wang, J., & Zhao, G. (2014) · Chemical Research in Chinese Universities · doi:10.1007/s40242-014-3257-1 · Cited by 3
Dapagliflozin: drug profile and its role in individualized treatment
Sposetti, G., Mackinnon, I. J., & Barengo, N. C. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.995636 · Cited by 3
“It is a powerful selective and reversible SGLT2 oral inhibitor [16].”
BackgroundAdvances in treatment of diabetic foot ulcers
Paola, L. D., Carone, A., Ricci, S., & Russo, A. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65001-6 · Cited by 4
Li, Z., Wang, X., Xu, X. J., Qiu, Q., Jiao, L., Huang, W., & Qian, H. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12547 · Cited by 3
“Dapagliflozin was synthesized as previously reported (9).”
Kuroda, S., Kobashi, Y., Kawamura, M., Kawabe, K., Shiozawa, F., Hamada, M., Shimizu, Y., Okumura-Kitajima, L., Koretsune, H., Kimura, K., et al. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00089 · Cited by 3
Evaluation of Dapagliflozin in the Treatment of Heart Failure
Sotirakos, S. (2020) · Future Cardiology · doi:10.2217/fca-2020-0138 · Cited by 3
The (Poly)phenol-Carbohydrate Combination for Diabetes: Where Do We Stand?
de Matos, A. M., & Menezes, R. (2023) · Nutrients · doi:10.3390/nu15040996 · Cited by 3
“SGLT1 IC50 50,000 nM [18]) sees its potency enhanced with the introduction of an O-glucosyl moiety (SGLT2 IC50 21–67 nM vs.”
BackgroundDapagliflozin: a new adjunct in the treatment of Type 2 diabetes mellitus
Sachdeva, M., Dhingra, S., & Parle, M. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20140805 · Cited by 3
Development and Recent Advancement of SGLT2 Inhibitors for the Treatment Regime of T2DM
Pathania, S., Kashyap, N., Singh, V., Shankar, R., Kumar, K., & Rawal, R. K. (2016) · Journal of Biomedicine · doi:10.5812/jmb.10052 · Cited by 3
“Finally, 9 was subjected to lithium halogen exchange, peracetylation and hydrolysis with lithium hydroxide to yield desired product dapagliflozin (29).”
BackgroundMethodInfluentialHuang, F., Dai, F., Bi, J., Hao, L., Wang, C., Xu, K., Liu, Y., & Cheng, X. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13130 · Cited by 3
“Dapagliflozin was synthesized based on reported procedure.([16]) Purity of tested compounds was more than 98%.”
MethodDiabetic Nephropathy – Research
Maestroni, S., & Zerbini, G. (2020) · Wiley eBooks · doi:10.1002/9781119309642.ch8 · Cited by 3
Rodríguez‐Zavala, J. S., & Zazueta, C. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400492 · Cited by 2
Shaker, A. M., Rakha, N. K., Keshk, A. A. M., & Din, U. A. S. E. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02757-x · Cited by 2
“Uremic milieu disrupts MSCs function [31].”
Kianfar, T., Fallah, M., Ramezani, F., Rakhshan, K., Najafzadeh, E., & Azizi, Y. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001795 · Cited by 3
Tyagi, R., Yadav, Y., Gupta, K., Kumar, E. S. S., Dubey, K. D., & Sagar, R. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501178 · Cited by 2
He, S., Wu, Z., & Li, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1808167 · Cited by 5
(5-Bromo-2-methoxyphenyl)(4-ethylcyclohexyl)methanone
Wang, L., Chang, Z.-Q., Ding, C.-L., Shao, H., & Sun, J.-Z. (2011) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536811013687 · Cited by 2
“SGLT2 inhibitors are a class of promising anti-hyperglycemic agents, and a variety of SGLT2 inhibitors are now in clinical trials (Meng et al., 2008).”
BackgroundMichigami, K., Shimazaki, A., & Hayashi, M. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201301376 · Cited by 2
Banerjee, B., Kaur, M., Singh, A. K., Sharma, A., & Priya, A. (2024) · Current Green Chemistry · doi:10.2174/0122133461339667240910052814 · Cited by 2
Palladium(0)-catalyzed synthesis of cyclic glucosides
Huang, X., Fu, C., & Ma, S. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01975j · Cited by 2
Imran, H. M., Nester, W. A., Elgendy, I. Y., & Saad, M. S. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1767298 · Cited by 2
de Matos, A. M., Calado, P., Miranda, M., Almeida, R., Rauter, A. P., Oliveira, M. C., Manageiro, V., & Caniça, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-51428-6 · Cited by 3
Takemiya, K., Seo, W., Voll, R. J., Zhao, S., Joseph, G., Wang, S., Zeng, F., Nye, J. A., Murthy, N., Taylor, W. R., et al. (2025) · RSC Advances · doi:10.1039/d5ra00693g · Cited by 2
Cao, M., Guo, Y., Tan, W., Feng, C., Chen, Q., Yao, M., Xu, J., Chen, Z., & Li, Q. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117585 · Cited by 2
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“Final reduction, peracetylation, and hydrolysis yielded da-pagliflozin [134].”
The stereoselective syntheses of 1-aryl-1,6-dideoxyinositol derivatives
Bian, J., Schneider, S. R., & Maguire, R. J. (2011) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.07.066 · Cited by 2
Cao, K., Brailsford, J. A., Yao, M., Caceres‐Cortes, J., Espina, R. J., & Bonacorsi, S. J. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3484 · Cited by 2
Effect of Dapagliflozin on Prognosis of Patients with Heart Failure with Reduced Ejection Fraction
杨, 欣. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111786 · Cited by 2
Salehi, M., Rayatpisheh, N., Salehi, M., & Mardanparvar, H. (2023) · Journal of Renal Endocrinology · doi:10.34172/jre.2023.25095 · Cited by 2
“And, dapagliflozin showed over 1200-fold higher potency for human SGLT2 compared to SGLT1 in C-glucoside analogs, which were developed similarly (26).”
BackgroundMiyatake, Y., Izumi-Mishima, Y., Tsutsumi, R., Otani, T., Suemasa, N., Masumoto, S., Kuroda, M., & Sakaue, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.165 · Cited by 2
Auld, D., Simeonov, A. M., & Thomas, C. J. (2008) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.9995 · Cited by 2
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes
Corsino, L., Cox, M. E., Rowell, J. V., & Green, J. B. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2109 · Cited by 2
gem -Dimethyl-bearing C -Glucosides as Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors
Shi, Y., Zhao, G., Lou, Y., Wang, Y., Shao, H., Liu, W., Xu, W., & Tang, L. (2011) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201190222 · Cited by 2
Vertical sleeve gastrectomy lowers kidney SGLT2 expression in the mousePreprint
Akalestou, E., López–Noriega, L., Leclerc, I., & Rutter, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/741330 · Cited by 2
Glycosyltransferase Cascades Made Fit For the Biocatalytic Production of Natural Product Glycosides
Nidetzky, B. (2021) · Wiley eBooks · doi:10.1002/9783527824465.ch8 · Cited by 2
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
Shao, H., Zhao, G., Liu, W., Wang, Y., & Xu, W. (2009) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536809047151 · Cited by 1
“Dapagliflozin is an anti-diabetic agent through the inhibition of renal SGLT2, which is developed by Bristol-Myers Squibb Company, and now it is in the phase III clinical trial (Meng et al., 2008).”
BackgroundSynthesis of C-Arylglucosides as SGLT2 Inhibitors
Murakata, M. (2021) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.79.532 · Cited by 1
Antidiabetic drugs based on sodium-glucose cotransporter 2 inhibitors
Niu, Y., & Ye, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00023-1 · Cited by 2
Miyamoto, L., Nakayama, S., Endoh, H., Fujiwara, K., Hattori, M., Yasuoka, T., Imanishi, M., Ikeda, Y., & Tsuchiya, K. (2026) · HORMONES · doi:10.1007/s42000-026-00805-z · Cited by 1
Chu, D.-J., Xie, X., Sheng, R., & Jin, J. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00302 · Cited by 1
Effects of Dapagliflozin on Novel Inflammatory Markers in Heart Failure Patients
Şenöz, O., & Sezen, M. (2026) · Cardiology Research and Practice · doi:10.1155/crp/5537675 · Cited by 1
Matei, D. P., Ghișe, A. D., Cărpinişan, L., Hutu, I., Stancu, A., Imre, K., & Dumitrescu, E. (2026) · Pharmaceuticals · doi:10.3390/ph19030376 · Cited by 1
“…resveratrol and viniferin specification. https://doi.org/10.3390/ph19030376 inhibition [43] direct potent and selective hSGLT2 3 inhibitor [37,38] direct potent SGLT2 inhibitor [37] direct dual inhibitor: SGLT1 and SGLT2 [8,37] indirect inhibitor of SGLT1 [10,48,62,67] binds to membrane…”
InfluentialYang, J., Li, X., Tang, L., Fan, W., Li, A., Zhou, W., Pang, J., Yuan, Q., Zhong, M., Hou, J., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05757-1 · Cited by 1
“SGLT2 inhibitors represent a novel class of hypoglycemic agents, and multiple studies have confirmed their clinical benefits in patients with T2DM [23–25].”
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Scheeff, S., Arakelyan, J., & NG, B. K. W. (2026) · Israel Journal of Chemistry · doi:10.1002/ijch.70017 · Cited by 2
Montasser, M. E., Bargal, S. A., Streeten, E. A., Whitlatch, H. B., Yazdi, Z. S., Sirody, J., Kiplagat, R., Beshara, M., O’Connell, J. R., Taylor, S. I., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70594 · Cited by 1
(5-Bromo-2-hydroxyphenyl)(4-propylcyclohexyl)methanone
Kang, M., Cao, M., An, Z., Zhang, J., & Liu, L.-H. (2012) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536812011634 · Cited by 1
“SGLT2 inhibitors represent a new class of potential hypoglycemic agents (Meng et al., 2008).”
BackgroundA Short Review On Anti-Diabetic Agent
Gautam, D. (2014) · Pharmatutor · Cited by 1
Therapeutic Potential of SGLT2 Inhibitors in Treating Type 2 Diabetes Mellitus
Amin, M., & Suksomboon, N. (2014) · Cited by 1
Target Validation—Prosecuting the Target
Jones, L. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00014-1 · Cited by 1
Review of Pharmaceutical and Therapeutic Approaches for Type 2 Diabetes and Related Disorders
Saeedi, M., Mehranfar, F., Ghorbani, F., Eskandari, M., Ghorbani, M., & Babaeizad, A. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220128102934 · Cited by 1
Synthesis of SGLT-2 Inhibitors
Ragan, J. A., Nelson, J. D., Brandt, T. A., & Robinson, R. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-32-390644-9.00060-3 · Cited by 1
Kilaru, G. G. K., Pagadala, R., Gutta, M., Konabatula, C. S., Rajkumar, S. T., Gundekari, S., & Varkolu, M. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2024.101557 · Cited by 1
Kula, A. J. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00684-8 · Cited by 1
“There are several SGLT2i on the market, and their efficacy and safety are believed to be very similar [16].”
Kidneys function in glucose homeostasis regulation and its therapeutic implications
Otto-Buczkowska, E., & Tucholski, K. (2013) · Family Medicine & Primary Care Review · Cited by 3
Construction of C-glucoside in SGLT2 Inhibitors
Kakinuma, H., & Oi, T. (2016) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.74.949 · Cited by 1
Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Gupta, A., Mittal, S., Monika, Dhingra, R., & Dhingra, N. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666200117155016 · Cited by 1
Advances in Micro-Bioreactor Design for Organ Cell Studies
Mandenius, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-232-7 · Cited by 1
Shah, N., Perkovic, V., & Kotwal, S. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108402 · Cited by 3
“gliflozin which contains a novel C-glycosylated diarylmethane pharmacophore making it selective for the SGLT-2 transporter [112].”
BackgroundMascitti, V., & Robinson, R. P. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527676545.ch09 · Cited by 1
Still Uncertain About Sodium–Glucose Cotransporter Inhibitors Despite 2 Centuries of Study
Smith, S. A. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00012 · Cited by 1
“Dapagliflozin, the first in the class of selective renal sodium–glucose cotransporter (SGLT) inhibitors (1), offers a novel, insulin-independent mechanism of action for diabetes treatment.”
Background2-(5-Bromo-2-methylphenyl)propan-2-ol
Zeng, H., & Liu, X. (2010) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536810042698 · Cited by 1
“Comment The title compound, whose crystal structure is reported herein, is an important intermediate for the synthesis of SGLT2 inhibitors possessing potent antihyperglycemic activity (Gao et al., 2010; Meng et al., 2008; Wang et al., 2010).”
BackgroundA translational viewpoint explaining its potential salutary effects
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw015 · Cited by 1
Krofchick, D. (2012) · TSpace (University of Toronto) · Cited by 1
Ritter, K. (2018) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a03_001.pub3 · Cited by 2
Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
Washburn, W. N. (2015) · Wiley eBooks · doi:10.1002/9783527678433.ch5 · Cited by 1
Self-citationDapagliflozin for adults with type 2 diabetes mellitus
Raval, A. D., Chovatiya, K., Bhavsar, A. B., & Patel, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009001
Self-citationRegulation of renal brush-border glucose transport in response to metabolic dysregulation
Chichger, H. (2011) · UCL Discovery (University College London)
Inhibiteurs de SGLT2 dans le diabète de type 1 : vraie perspective ou fausse bonne idée ?
Darmon, P. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30058-4
Escalada, J., & Rodríguez, F. J. S. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65012-0
Rajaratnam, H., & Kahandawa, S. (2012) · Sri Lanka Journal of Diabetes Endocrinology and Metabolism · doi:10.4038/sjdem.v2i1.4331
“Dapagliflozin is the first in a novel class of glucoselowering medications, the selective sodium-glucose cotransporter 2 (SGLT2) inhibitors (16).”
Background1-(5-Bromo-2-chlorophenyl)-2,2-dichloro-1-(4-ethoxyphenyl)cyclopropane
Han, S., Shi, Y., Yuli, W., Zhao, G., & Xu, W. (2013) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536813003735
“The most advanced drug, dapagliflozin, has recently been approved in EU (Meng et al., 2008; Washburn, 2009).”
BackgroundSelf-citationCanagliflozin Potently Activates AMPK and Inhibits the Growth and Survival of Cancer Cells
Villani, L. A. (2015) · MacSphere (McMaster University) · doi:10.71548/8610
(5-Bromo-2-methylphenyl)(4-ethoxyphenyl)methanone
Shi, Y., Zhao, G., Shao, H., Liu, W., & Xu, W. (2010) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536810027327
“Dapagliflozin is an anti-diabetic agent through the inhibition of renal SGLT2, which was developed by Bristol-Myers Squibb Company and is now in the phase III clinical trial (Meng et al., 2008).”
BackgroundSodium‐Glucose Cotransporter‐2 Inhibitors
Barnett, A. H., & Grice, J. (2011) · Wiley eBooks · doi:10.1002/9781118682197.ch6
Sodium Glucose Cotransporter 2 Inhibitors
Ryan, M., & Jabbour, S. A. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch13
4-Bromo-2-[1-(4-ethoxyphenyl)-1-methylethyl]-1-methylbenzene
Li, Y., Kong, X., Chen, G., Jian-guo, C., & Wang, J. (2010) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536810049445
The Discovery of the Dipeptidyl Peptidase-4 (DPP4) Inhibitor Onglyza™: From Concept to Market
Robl, J. A., & Hamann, L. G. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849731980-00001
Dapagliflozin: a selective sodium-glucose co-transporter-2 inhibitor in type 2 diabetes.
Pemminati, S., Shenoy, A. K., Yugandhar, B., Sd, U., Up, R., Gopalakrishna, H. N., Pai, P. G., & Rajeshwari, R. (2011)
[Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
Wan, H.-X., & Shen, J. (2012) · PubMed
cotransporters SGLT1 and SGLT2 /d-glucose + Glucose transport by human renal Na
Wright, E. M., Hummel, C. S., Lü, C., Loo, D. D. F., Hirayama, B. A., & Voss, A. A. (2016)
Progress Research on Novel Anti-Diabetes Drugs Based on SGLT2 Receptor Protein
Chen, F., Gong, P., & Zhou, A. (2012)
Relevancia clínica de la selectividad de los inhibidores del cotransportador sodio-glucosa tipo 2
Morales‐Olivas, F. J. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30622-x · Cited by 2
5-(4-Ethoxybenzyl)-1H-tetrazole
Gao, Y., Zhao, G., Shao, H., Liu, W., & Wang, J. (2010) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536809055597
“Related literature For details of the biological activities of sodium-glucose cotransporter 2 (SGLT2) inhibitors, see: Arakawa et al. (2001); Meng et al. (2008).”
BackgroundSaad, M., Gomceli, U., Ravi, P., Lacoste, A. G., Shah, N., & Vittorio, T. J. (2018) · Drugs in Context · doi:10.7573/dic.212549
Bai, J. D. K. (2015) · TSpace (University of Toronto)
Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes
Jesus, A. R., Harrison, B. A., & Dore, T. M. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc277
Cortés, A. M. T. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/178231
Escalada, J., & Rodríguez, F. J. S. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)66014-0
Light-Mediated Cross-Coupling of Anomeric TrifluoroboratesPreprint
Miller, E., & Walczak, M. A. A. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14347460
Ahmed, D., Sharma, M., Kumar, V., & Yadav, P. S. (2012) · Nature Precedings · doi:10.1038/npre.2012.7057
Sodium-Glucose Cotransporter 2 Inhibitors
DAILEY, G. E., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_36
Time to completely eradicate diabetic nephropathy
Din, U. A. S. E., Salem, M. M., & Abdulazim, D. O. (2023) · Diabetic Nephropathy · doi:10.1515/dine-2023-0005 · Cited by 1
Using PET imaging as tool to unravel drug response variability in type 2 diabetes
van der Hoek, S. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.845383131
Choutka, J., Parkan, K., Pohl, R., & Kaminský, J. (2023) · Carbohydrate Research · doi:10.1016/j.carres.2023.109021
Empagliflozina, Inibidor do SGLT2 no Tratamento da Diabetes do Tipo 2
Gamito, C., Guidara, C. L., & Costa, J. R. (2024) · Boletim da Sociedade Portuguesa de Química · doi:10.52590/m3.p709.a30002770
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.